Better Survival With S-1/Docetaxel in Stage III Gastric Cancer
Postoperative adjuvant S-1/docetaxel after D2 gastrectomy significantly improved survival in comparison with S-1 alone for patients with stage III gastric cancer. Medscape Medical News